BH Share Price Performance
฿185.00
-10.00 (-5.13%)
15.6% overvalued intrinsic discount
฿160.00
Fair Value
Price ฿185.00
AnalystLowTarget ฿160.00
AnalystConsensusTarget ฿214.62
AnalystHighTarget ฿240.00
Fair Value฿160.00
Share Pricen/a
Bumrungrad Hospital Public Company Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
BH Community Narratives
AN
Fair Value ฿160 15.6% overvalued intrinsic discount
Middle East Instability And Rising Wages Will Hurt Performance
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ฿214.62 13.8% undervalued intrinsic discount
New Cancer Center And Robotic Surgery Will Expand Global Capacity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ฿240 22.9% undervalued intrinsic discount
Digital Health And Medical Tourism Will Transform Southeast Asia Healthcare
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Digital Health And Medical Tourism Will Transform Southeast Asia Healthcare
Key Takeaways Advanced cancer care, AI diagnostics, and wellness initiatives position Bumrungrad to dominate regional markets and deliver higher, recurring revenue with improved margins. Expansion into medical tourism centers and restoration of Gulf region partnerships will significantly broaden the international patient base and drive earnings growth.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
฿240
22.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.67% p.a.
Profit Margin
25.64%
Future PE
26.62x
Price in 2029
฿295.72
Middle East Instability And Rising Wages Will Hurt Performance
Key Takeaways Heavy dependence on international medical tourists and geopolitical factors creates unpredictable revenue and heightens vulnerability to policy changes and travel restrictions. Intensifying regional competition, rising operational costs, and technological shifts threaten long-term growth, margins, and returns despite ongoing physical expansion.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
฿160
15.6% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.45% p.a.
Profit Margin
24.71%
Future PE
22.05x
Price in 2028
฿198.39
New Cancer Center And Robotic Surgery Will Expand Global Capacity
Key Takeaways Expansion into advanced oncology, preventative medicine, and robotic surgery is strengthening high-margin service offerings and broadening the addressable market. Recovery in international patient flows and insurance partnerships is enhancing revenue diversification and supporting long-term earnings resilience.Read more
48
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
฿214.62
13.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
5.51% p.a.
Profit Margin
27.07%
Future PE
26.19x
Price in 2028
฿266.11
Trending Discussion
Recently Updated Narratives
AN
BH: Adjusted Margins And Multiple Will Still Support An Undervalued Outlook
Fair Value: ฿240 22.9% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BH: Future Revenue Outlook Will Offset Slight Margin Compression And Maintain Fair Value
Fair Value: ฿160 15.6% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BH: Revenue Outlook Will Drive Attractive Upside Potential Ahead
Fair Value: ฿214.62 13.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bumrungrad Hospital Public Company Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 23, 2026
- 9.45
- 52.25%
- 29.52%
- 0.07%
About BH
- Founded
- 1975
- Employees
- n/a
- CEO
- WebsiteView website
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers. In addition, it operates spine institute, heart institute, and intensive care unit; and offers nutrition services, pharmacy services, preventive genomics and integrative medicine services. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
